Treatment Centers and Clinical Trials
You can restrict your search to only Treatment Centers or only Clinical Trials by checking the Treatment Center or Clinical Trial checkbox under TYPE. Use the Zoom-In (+ sign on the lower right of the map) to enlarge the map area to find your preferred location. To search for a Treatment Center or Clinical Trial, click on the red map pin for the name of the facility. Click on the name of the facility for more details.
Location
Treatments/Services
Type
OhioHealth Physician Group - Hematology/Oncology
ROCHESTER SKIN LYMPHOMA MEDICAL GROUP, PLLC
Rush University Medical Center
The University of Kansas Hospital
The Warren Alpert Medical School of Brown University, Department of Dermatology
Fred Hutch Cancer Center
Tulane University School of Medicine
University Dermatology Consultants, Inc.
University Hospitals of Cleveland
University of Alabama Medical Center
University of California, San Francisco
University of Iowa Hospitals & Clinics
University of North Carolina Medical Center
University of Pittsburgh Medical Center
University of Rochester - Wilmot Cancer Institute
University of Texas Southwestern Medical Center
University of Virginia-Emily Couric Clinical Cancer Center
University of Wisconsin - Madison
Vanderbilt University Medical Center
Atrium Health Wake Forest Baptist
Winship Cancer Institute - Emory University
Mayo Clinic - Arizona Campus
Cleveland Clinic
Clinical Cancer Center, Froedtert Hospital
Saint Louis University Cancer Center
Washington University Medical Center - Siteman Cancer Center
The Dermatology Clinic at University of Minnesota
Henry Ford Hospital - Cutaneous Lymphoma Program
University of Michigan Medical Center
Northwestern Medicine
Yale University School of Medicine
Penn Cutaneous Lymphoma Program
Jefferson Cutaneous Lymphoma Clinic
Boston Medical Center - Cutaneous Oncology Program
Center for Cutaneous Oncology at Dana-Farber/Brigham Cancer Institute
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
INOVA Melanoma and Skin Oncology Center
Dartmouth Hitchcock Medical Center
Columbia University Irving Medical Center - Cutaneous Lymphoma Center
NYU Grossman School of Medicine
University of Texas MD Anderson Cancer Center
Moffitt Cancer Center
Cleveland Clinic - Indian River Hospital
Miami Cancer Institute BHSF
Levine Cancer Institute
Duke Cutaneous T-Cell Lymphoma Clinic and Research Center
UCHealth - University of Colorado Cancer Center - Anschutz
Huntsman Cancer Institute
Stanford Medical Center (Multidisciplinary Cutaneous Lymphoma Clinic)
Oregon Health & Science University (OHSU)
MUSC Cutaneous Lymphoma Clinic
Johns Hopkins Dermatology
OU Physicians
City of Hope National Medical Center
Chao Family Comprehensive Cancer Center
Mayo Clinic - Florida
Fondazione IRCCS Ca' Granda
IU Simon Cancer Center
Peter MacCallum Cancer Centre
Westmead Hospital - University of Sydney
Medical University of Graz
Medical University of Vienna
Hôtel-Dieu - CHU de Nantes
Hospital Dresden-Friedrichstadt
Charité University of Medicine Berlin
HELIOS Klinikum Krefeld
Rabin Medical Center
Rambam Medical Center
Spedali Civili di Brescia
Cutaneous Lymphoma Multidisciplinary Clinic - Lisbon
Friedrich Schiller University - Hospital Jena
University Medical Centre - Mannheim
University of Essen
Semmelweis Medical School
Hospital Universitario 12 de Octubre
Mt Sinai - Kimberly and Eric J. Waldman Dept of Dermatology
University Hospital Zurich - Department of Dermatology
Memorial Sloan Kettering Cancer Center
John Theurer Cancer Center at HUMC
Emil P. Bisaccia, MD, Center for Photopheresis at Morristown Medical Center
Johann Wolfgang Goethe-University Frankfurt
OSU Comprehensive Cancer Center
Roswell Park Comprehensive Cancer Center
St. Thomas Hospital - St Johns Department of Dermatology
UAMS Cancer Center
Newnan Dermatology
Rixis Dermatology
Medical Dermatology Specialists
Phase 1 Trial of ST-001 nanoFenretinide
Description
Pembrolizumab - Stage IB-IV Mycosis Fungoides
Brief Summary:
This phase II trial studies how well pembrolizumab works in treating patients with stage IB-IV mycosis fungoides. Antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread.
For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.
Dose-Escalation Trial Evaluating CPI-818
Brief Summary:
This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability, and anti-tumor activity of CPI-818 as a single drug. This trial is composed of dose escalation and dose expansion cohorts.
For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.
Duvelisib + Nivolumab for the Treatment of MF and SS
Brief Summary:
Extracorporeal Photopheresis in Sezary Syndrome (ECP)
Brief Summary:
Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
Brief Summary:
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTC
Brief Summary:
This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs) and to evaluate the clinical efficacy at the MTD of various combinations of pembrolizumab, pralatrexate and decitabine.
For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.
Real World Observational Study of Poteligeo in Adult Patients With MF and SS
Brief Summary
This is a prospective, observational, non-interventional, international, multi-center, mixed methods study that will involve the integration of quantitative and qualitative data in patients with MF/SS treated with Poteligeo.
For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Ly
Brief Summary
Pembrolizumab in Combination With Gemcitabine in People With Advanced MF or SS
Brief Summary
The purpose of this study is to find out whether the combination of pembrolizumab and gemcitabine is an effective treatment for mycosis fungoides and Sézary syndrome.
For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.
Website: https://clinicaltrials.gov/study/NCT04960618#contacts-and-locations
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Brief Summary
The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.
For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.
Website: https://clinicaltrials.gov/study/NCT03587844
Sponsors: Memorial Sloan Kettering Cancer Center
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Brief Summary
This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma.
Website: https://clinicaltrials.gov/study/NCT05010005
Sponsor: Memorial Sloan Kettering Cancer Center
Eligibility Criteria
Permitted histologies include:
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Brief Summary
This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma.
For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.
Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light (RW-HPN
Brief Summary
The goal of this clinical trial is to assess the benefit of continuous treatment with synthetic hypericin ointment (HyBryte) and visible light in patients with mycosis fungoides for up to 12 months (54 weeks). Funding Source: FDA OOPD.
For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.
Ritlecitinib in CTCL
Brief Summary
The purpose of this research study is to evaluate the effectiveness and safety of Ritlecitinib in skin and blood in persons with Cutaneous T-Cell Lymphoma (CTCL). CTCL is a rare type of cancer that starts in the white blood cells and eventually can result in rashes or tumors in the skin. This study includes a 24 week Treatment Period and a 24 week Follow-up Period. This study will involve physical examinations, visual assessments, laboratory tests, PET-CT scans, electrocardiograms, photographs of your skin, skin biopsies, and hearing tests.